China Shineway Pharmaceutical Group Limited
CSWYY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.01 | 0.01 | 0.01 |
| FCF Yield | 322.23% | 312.14% | 620.91% | 229.68% |
| EV / EBITDA | -4.54 | -3.76 | -4.40 | -4.34 |
| Quality | ||||
| ROIC | 7.79% | 10.25% | 8.58% | 6.78% |
| Gross Margin | 74.95% | 75.15% | 74.38% | 74.77% |
| Cash Conversion Ratio | 0.84 | 0.75 | 1.54 | 1.26 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.48% | 11.90% | 14.16% | 6.01% |
| Free Cash Flow Growth | 4.40% | -19.58% | 60.82% | 6.46% |
| Safety | ||||
| Net Debt / EBITDA | -4.75 | -3.93 | -4.55 | -4.64 |
| Interest Coverage | 137.48 | 356.42 | 1,132.66 | 426.13 |
| Efficiency | ||||
| Inventory Turnover | 1.16 | 1.25 | 1.54 | 1.38 |
| Cash Conversion Cycle | 274.34 | 236.13 | 215.89 | 160.79 |